Across TCGA pan-cancer cohorts, RN7SL217P RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RN7SL217P’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where RN7SL217P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL217P is over-expressed in tumor.
STAD are the cancer types where RN7SL217P tumor–normal differential expression is most reproducible.